PMID- 28932367
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2008-6164 (Print)
IS  - 2008-6172 (Electronic)
IS  - 2008-6164 (Linking)
VI  - 8
IP  - 3
DP  - 2017 Summer
TI  - Double strain probiotic effect on Helicobacter pylori infection treatment: A 
      double-blinded randomized controlled trial.
PG  - 165-171
LID - 10.22088/cjim.8.3.165 [doi]
AB  - BACKGROUND: A decreased rate of successful helicobacter pylori (H.pylori) 
      infection treatment has revealed serious demand for more effective regimens to 
      eradicate infection. Therefore, probiotics have recently been considered to 
      increase the rate of antibiotic regimens efficacy in H. pylori infections. In 
      current randomized controlled trial, we evaluated the effect of double strain 
      probiotic combination with standard triple therapy (STT), in the eradication rate 
      of H. pylori infection. METHODS: In current randomized placebo-control study, all 
      patients (176 subjects) underwent the STT for 10 days. However, the study group 
      received triple therapy for the eradication of H. pylori with supplement of 
      Lactobacillus probiotic for 4 weeks and placebo was administered to control 
      group, as well. Adverse effects of the antibiotic regimen were recorded for all 
      patients. Six weeks after the cessation of probiotic intake, all patients 
      underwent H. Pylori with fecal antigen of test, followed by a recurrence 
      evaluation six months later. RESULTS: There was no significant difference in 
      demographic data and presenting symptoms between the study groups. The 
      eradication rate of H. pylori infection was significantly higher in probiotic 
      group (78.4%), compared to that of placebo group (64.8%) (P=0.033). In addition, 
      adverse events were significantly less prevalent in patients that received 
      probiotic (P=0.047). Nonetheless, there was no significant difference in terms of 
      infection recurrence during a 6-month follow-up (P=0.07). CONCLUSION: Double 
      strain probiotic in combination with STT increased the eradication rate of H. 
      pylori infection, while the adverse events due to antibiotic therapy decreased.
FAU - Haghdoost, Mehdi
AU  - Haghdoost M
AD  - Department of Infectious Diseases, Tabriz University of Medical Sciences, Tabriz, 
      Iran.
FAU - Taghizadeh, Sepehr
AU  - Taghizadeh S
AD  - Department of Infectious Diseases, Tabriz University of Medical Sciences, Tabriz, 
      Iran.
FAU - Montazer, Majid
AU  - Montazer M
AD  - Department of Cardiothoracic Surgery, Tabriz University of Medical Sciences, 
      Tabriz, Iran.
FAU - Poorshahverdi, Parinaz
AU  - Poorshahverdi P
AD  - Department of Infectious Diseases, Tabriz University of Medical Sciences, Tabriz, 
      Iran.
FAU - Ramouz, Ali
AU  - Ramouz A
AD  - Research Fellow, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Fakour, Sanam
AU  - Fakour S
AD  - Research Fellow, Tabriz University of Medical Sciences, Tabriz, Iran.
LA  - eng
PT  - Journal Article
PL  - Iran
TA  - Caspian J Intern Med
JT  - Caspian journal of internal medicine
JID - 101523876
PMC - PMC5596186
OTO - NOTNLM
OT  - Helicobacter pylori
OT  - Lactobacillus
OT  - Probiotic
OT  - Recurrence
OT  - Standard triple therapy
COIS- None declared.
EDAT- 2017/09/22 06:00
MHDA- 2017/09/22 06:01
PMCR- 2017/06/01
CRDT- 2017/09/22 06:00
PHST- 2017/09/22 06:00 [entrez]
PHST- 2017/09/22 06:00 [pubmed]
PHST- 2017/09/22 06:01 [medline]
PHST- 2017/06/01 00:00 [pmc-release]
AID - 10.22088/cjim.8.3.165 [doi]
PST - ppublish
SO  - Caspian J Intern Med. 2017 Summer;8(3):165-171. doi: 10.22088/cjim.8.3.165.